Immunomedics to Report Results for the Quarter and Six Months Ended December 31, 2018 and Host Conference Call and Webcast on February 25, 2019
February 19, 2019 08:00 ET
|
Immunomedics
MORRIS PLAINS, N.J., Feb. 19, 2019 (GLOBE NEWSWIRE) -- Immunomedics, Inc., (NASDAQ: IMMU) (“Immunomedics” or the “Company”), a leading biopharmaceutical company in the area of antibody-drug...
Immunomedics Announces Oral Presentation at the 2019 Genitourinary Cancers Symposium
February 11, 2019 17:15 ET
|
Immunomedics
MORRIS PLAINS, N.J., Feb. 11, 2019 (GLOBE NEWSWIRE) -- Immunomedics, Inc., (NASDAQ: IMMU) (“Immunomedics” or the “Company”), a leading biopharmaceutical company in the area of antibody-drug...
Immunomedics and Johnson Matthey Announce Strategic Manufacturing Partnership
December 26, 2018 08:00 ET
|
Immunomedics
MORRIS PLAINS, N.J. and DEVENS, Mass., Dec. 26, 2018 (GLOBE NEWSWIRE) -- Immunomedics, Inc., (NASDAQ: IMMU) and Johnson Matthey (LSE: JMAT), today announced the companies have expanded their...
Immunomedics Announces Presentation at Upcoming Healthcare Conferences
November 08, 2018 08:00 ET
|
Immunomedics
MORRIS PLAINS, N.J., Nov. 08, 2018 (GLOBE NEWSWIRE) -- Immunomedics, Inc., (NASDAQ: IMMU) (“Immunomedics” or the “Company”), a leading biopharmaceutical company in the area of antibody-drug...
Immunomedics Announces First Quarter Fiscal 2019 Results and Provides Corporate Update
November 07, 2018 16:05 ET
|
Immunomedics
Strategic Manufacturing Partnership Entered into with Samsung BioLogics to Provide Anticipated Long-Term Supply of Sacituzumab Govitecan Commercial Launch Preparations Nearing Completion with 50...